AstraZeneca’s supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) has been accepted and granted Priority Review in the US based on the results from the positive ADRIATIC Phase III trial in patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based concurrent chemoradiotherapy (cCRT).   Imfinzi was also recently granted Breakthrough Therapy Designation (BTD) by the FDA.   Small cell lung cancer (SCLC) is a high...